Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Treasury Shares (2021 - 2025)

Bioventus (BVS) has disclosed Treasury Shares for 5 consecutive years, with $159000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed N/A year-over-year to $159000.0, compared with a TTM value of $159000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $159000.0, changed N/A over the prior year.
  • Treasury Shares was $159000.0 for Q4 2025 at Bioventus, down from $2.8 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $3.9 million in Q1 2024 and bottomed at $159000.0 in Q4 2025.
  • Average Treasury Shares over 5 years is $1.7 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Treasury Shares skyrocketed 593.69% in 2022, then dropped 25.16% in 2025.
  • Year by year, Treasury Shares stood at $1.0 million in 2021, then grew by 16.11% to $1.2 million in 2022, then surged by 73.76% to $2.1 million in 2023, then surged by 35.53% to $2.8 million in 2024, then tumbled by 94.32% to $159000.0 in 2025.
  • Business Quant data shows Treasury Shares for BVS at $159000.0 in Q4 2025, $2.8 million in Q3 2025, and $2.9 million in Q2 2025.